AC Immune SA (ACIU +2.4%) perks up, albeit on below-average volume, in apparent sympathy with the rally in Biogen on the news that the FDA has accepted the latter’s application for aducanumab for patients with early-stage Alzheimer’s disease (AD).
ACIU is also developing a treatment for early AD, anti-phospho-Tau vaccine ACI-35.030. A 24-subject Phase 1b/2a study is ongoing with an estimated primary completion date in October 2022. It is developing the asset, including ACI-35, with collaboration partner Janssen Pharmaceutical Company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.